All In Biotech

Drug Trial Radar · NCT07146906

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Jul 12, 2030

Study completion Oct 18, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Conditions

  • Immunoglobulin A Nephropathy (IgAN)

Interventions

  • zigakibartBiological

    zigakibart 600 mg sc injections every second week for 104 weeks (2 years)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in mesangial IgA depositionTime frame: Baseline to Week 53 or 105

Locations

30 sites in 11 countries. Site status is shown where the registry gives one.

  • UC San Francisco Medical Center

    San Francisco, California · Recruiting

  • Colorado Kidney Care Nephrology

    Denver, Colorado · Recruiting

  • American Clinical Trials

    Acworth, Georgia · Recruiting

  • Univ Of Iowa Hospitals And Clinics

    Iowa City, Iowa · Recruiting

  • Inter Med Consultants

    Edina, Minnesota · Recruiting

  • Novartis Investigative Site

    Serra, Espírito Santo, Brazil · Recruiting

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil · Recruiting

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Novartis Investigative Site

    Botucatu, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Hanover, Germany · Recruiting

  • Novartis Investigative Site

    Mainz, Germany · Recruiting

  • Novartis Investigative Site

    Munich, Bavaria, Germany · Recruiting

  • Novartis Investigative Site

    Ranica, BG, Italy · Recruiting

  • Novartis Investigative Site

    Brescia, BS, Italy · Recruiting

  • Novartis Investigative Site

    Pavia, PV, Italy · Recruiting

  • Novartis Investigative Site

    Miyazaki, Japan · Recruiting

  • Novartis Investigative Site

    Kawasaki, Kanagawa, Japan · Recruiting

  • Novartis Investigative Site

    Lodz, Poland · Recruiting

  • Novartis Investigative Site

    Opole, Poland · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Seville, Spain · Recruiting

  • Novartis Investigative Site

    Pamplona, Navarre, Spain · Recruiting

  • Novartis Investigative Site

    Valencia, Valencia, Spain · Recruiting

  • Novartis Investigative Site

    Kaohsiung City, Taiwan · Recruiting

  • Novartis Investigative Site

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.